Mitral Valve Insufficiency
Greater operator, hospital mitral valve surgery volume tied to reduced mortality, more repair
SAN FRANCISCO — Higher operator and hospital volume conferred better results for 30-day operative mortality, successful repair of primary mitral regurgitation and 1-year mortality, according to a presentation at TCT 2019.
COAPT: MitraClip benefit maintained at 3 years in HF, mitral regurgitation
SAN FRANCISCO — The treatment effect of transcatheter mitral valve repair in patients with HF and moderate-to-severe or severe mitral regurgitation was even greater at 3 years than it was at 2 years, according to new data from the COAPT trial presented at TCT 2019.
Operator experience plays key role in optimizing outcomes with transcatheter mitral valve repair
SAN FRANCISCO — Greater operator experience with transcatheter mitral valve repair using the MitraClip was associated with improvements in procedural success, time and complications, according to new research presented at TCT 2019.
MITRA-FR: No change in death, unplanned HF hospitalization at 2 years
PARIS — In patients with HF with reduced ejection fraction and secondary mitral valve regurgitation, percutaneous mitral valve repair with MitraClip plus medical therapy offered no advantage over medical therapy alone for the outcomes of death and unplanned hospitalization for HF at 2 years.